Head and Neck Cancer Trial, Recruiting NCT03117946 Sponsor: Centre Hospitalier Universitaire de Besancon Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT03117946
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or head and neck cancer, confirmed by a laboratory test of tissue samples
  • People whose treatment plan involves radiation therapy and chemotherapy given at the same time, as a first treatment
  • People who are willing and able to give written consent to participate

Who may not be able to join:

  • People whose treatment plan involves radiation therapy and chemotherapy given separately (one after the other), radiation therapy alone, or a precise targeted form of radiation called stereotactic radiotherapy
  • People who have previously received a combined radiation and chemotherapy treatment for cancer
  • People currently taking immunotherapy, chemotherapy, or other medicines that suppress the immune system (although low-dose prednisone or prednisolone of 10 mg per day or less may be permitted — confirm with trial site)
  • People who have HIV, hepatitis C, or hepatitis B
  • People with certain medical or psychiatric health conditions or illnesses (confirm with trial site for specific details)
  • People who are under legal guardianship, curatorship, or other forms of legal protection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33370632212

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire de Besancon
Registry
ClinicalTrials.gov
Start date
29 May 2017
Est. completion
29 August 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

tumor antigen specific T-cell responses

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov